oxidopamine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 13 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the BACHD model of Huntington's disease we demonstrate that the vector can be kept in a continuous ON-state for extended periods of time." | 1.48 | Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018) |
| "Huntington's disease is an autosomal dominant hereditary neurodegenerative disorder characterized by severe striatal cell loss." | 1.31 | Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. ( Brundin, P; Castilho, RF; DiFiglia, M; Hansson, O; Petersén, A; Przedborski, S; Puschban, Z; Rice, M; Romero, N; Sapp, E; Sulzer, D, 2001) |
| "Adenosine A2 receptors were labeled and visualized by autoradiography in tissue sections of the human brain using the A2-selective agonist ligand [3H](2-p-(2-carboxyethyl)phenylamino)-5'-N-carboxamidoadenosine (CGS 21680)." | 1.28 | Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. ( Martinez-Mir, MI; Palacios, JM; Probst, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, S | 1 |
| Tereshchenko, J | 1 |
| Zimmer, V | 1 |
| Vachey, G | 1 |
| Pythoud, C | 1 |
| Rey, M | 1 |
| Liefhebber, J | 1 |
| Raina, A | 1 |
| Streit, F | 1 |
| Mazur, A | 1 |
| Bähr, M | 1 |
| Konstantinova, P | 1 |
| Déglon, N | 1 |
| Kügler, S | 1 |
| Choi, ML | 1 |
| Begeti, F | 1 |
| Oh, JH | 1 |
| Lee, SY | 1 |
| O'Keeffe, GC | 1 |
| Clelland, CD | 1 |
| Tyers, P | 1 |
| Cho, ZH | 1 |
| Kim, YB | 1 |
| Barker, RA | 1 |
| Vandeputte, C | 1 |
| Taymans, JM | 1 |
| Casteels, C | 1 |
| Coun, F | 1 |
| Ni, Y | 1 |
| Van Laere, K | 1 |
| Baekelandt, V | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| de Lago, E | 1 |
| Fernández-Ruiz, J | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Reynolds, DS | 1 |
| Carter, RJ | 1 |
| Morton, AJ | 1 |
| Hebb, MO | 1 |
| Robertson, HA | 1 |
| Guzman, R | 1 |
| Lövblad, KO | 1 |
| Meyer, M | 1 |
| Spenger, C | 1 |
| Schroth, G | 1 |
| Widmer, HR | 1 |
| Levivier, M | 1 |
| Donaldson, D | 1 |
| Petersén, A | 1 |
| Hansson, O | 1 |
| Puschban, Z | 1 |
| Sapp, E | 1 |
| Romero, N | 1 |
| Castilho, RF | 1 |
| Sulzer, D | 1 |
| Rice, M | 1 |
| DiFiglia, M | 1 |
| Przedborski, S | 1 |
| Brundin, P | 1 |
| Burton, S | 1 |
| Daya, S | 1 |
| Potgieter, B | 1 |
| Martinez-Mir, MI | 1 |
| Probst, A | 1 |
| Palacios, JM | 1 |
13 other studies available for oxidopamine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression | 2018 |
Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.
Topics: Animals; Brain; Corpus Striatum; Dentate Gyrus; Dopamine; Dopamine Antagonists; Female; Hippocampus; | 2014 |
Automated quantitative gait analysis in animal models of movement disorders.
Topics: Animals; Automation; Brain; Disease Models, Animal; Female; Gait; Huntington Disease; Intracranial T | 2010 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzazepines; Corpus Striatum; Disease Models, A | 1998 |
Motor effects and mapping of cerebral alterations in animal models of Parkinson's and Huntington's diseases.
Topics: Animals; Behavior, Animal; Brain; Brain Mapping; Corpus Striatum; Dextroamphetamine; Disease Models, | 1999 |
Imaging the rat brain on a 1.5 T clinical MR-scanner.
Topics: Animals; Artifacts; Blood-Brain Barrier; Brain; Brain Tissue Transplantation; Female; Huntington Dis | 2000 |
Metabolic changes after injection of quinolinic acid or 6-hydroxydopamine in the rat striatum: a time-course study using cytochrome oxidase and glycogene phosphorylase a histochemistry.
Topics: Animals; Autoradiography; Benzazepines; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamin | 2000 |
Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.
Topics: Aging; Animals; Ascorbic Acid; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Respons | 2001 |
Melatonin modulates apomorphine-induced rotational behaviour.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Hun | 1991 |
Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease.
Topics: Adenosine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Female; Guinea Pigs; Hu | 1991 |